Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Candel Therapeutics, Inc.CADL · Entity 4969 | Chief Financial Officer | February 28, 2022 | March 01, 2022 |
| Harvard Apparatus Regenerative Technology, Inc.BSTG · Entity 7501 | Director | March 14, 2018 | March 28, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Candel Therapeutics, Inc.
Report date February 28, 2022 · Filed March 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.12 · Expires 2032-02-28 | Direct | 110,000 |
Reported balance
After 2022-02-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-28 · Grant · Acquired 110,000 · Balance 110,000 F1: This option is subject to time-based and performance-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following the Grant Date, subject to the Reporting Person's continued service on each such vesting date; provided, however, that one-third of the shares underlying this option shall only become exercisable if the average market price of the Issuer's common stock equals or exceeds $13.50 for any ten consecutive trading days prior to or as of December 31, 2022, and an additional one-third of the shares underlying this option shall only become exercisable if the average market price of the Issuer's common stock equals or exceeds $20.00 for any ten consecutive trading days prior to or as of December 31, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is subject to time-based and performance-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following the Grant Date, subject to the Reporting Person's continued service on each such vesting date; provided, however, that one-third of the shares underlying this option shall only become exercisable if the average market price of the Issuer's common stock equals or exceeds $13.50 for any ten consecutive trading days prior to or as of December 31, 2022, and an additional one-third of the shares underlying this option shall only become exercisable if the average market price of the Issuer's common stock equals or exceeds $20.00 for any ten consecutive trading days prior to or as of December 31, 2022.
Harvard Apparatus Regenerative Technology, Inc.
Report date March 14, 2018 · Filed March 28, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,774 |
Reported balance
After 2018-03-14 transaction · row 1
1 source rowRow 1 · 2018-03-14 · Exercise / conversion · Acquired 912 · Balance 1,774 F1: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2018-03-14 | Direct | 0 |
Reported balance
After 2018-03-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-14 · Exercise / conversion · Disposed 912 · Balance 0 F1: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2022 Filed Mar 1, 2022 18:40 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0000899243-22-008377 · doc4.xml · derivative · entry 1 Canepa John J · CIK 0001589238 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2032-02-28 F1 · derivative.exercise_date: This option is subject to time-based and performance-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following the Grant Date, subject to the Reporting Person's continued service on each such vesting date; provided, however, that one-third of the shares underlying this option shall only become exercisable if the average market price of the Issuer's common stock equals or exceeds $13.50 for any ten consecutive trading days prior to or as of December 31, 2022, and an additional one-third of the shares underlying this option shall only become exercisable if the average market price of the Issuer's common stock equals or exceeds $20.00 for any ten consecutive trading days prior to or as of December 31, 2022. Read SEC document |
| July 29, 2021 Filed Aug 2, 2021 20:06 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | PurchaseCommon Stock | 10,125 | $8.00 | $81,000.00 |
DisclosureSEC source: 0000899243-21-031092 · doc4.xml · nonDerivative · entry 1 Canepa John J · CIK 0001589238 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,125 Read SEC document |
| March 14, 2018 Filed Mar 28, 2018 21:03 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | Exercise / conversionRestricted Stock Units · Derivative | 912 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001144204-18-017584 · tv489773_form4.xml · derivative · entry 2 Canepa John J · CIK 0001589238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 912 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. Read SEC document |
| March 14, 2018 Filed Mar 28, 2018 21:03 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | Exercise / conversionCommon Stock | 912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-18-017584 · tv489773_form4.xml · nonDerivative · entry 1 Canepa John J · CIK 0001589238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:16 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantRestricted Stock Units · Derivative | 18,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-015094 · v461954_4.xml · derivative · entry 2 Canepa John J · CIK 0001589238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,250 Underlying: Common Stock, par value $0.01 per share · 18,250 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units granted by the Issuer pursuant to its 2013 Equity Incentive Plan and qualified under Rule 16b-3(d). Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F3 · derivative.exercise_date: The restricted stock units vest and settle in full one year from the date of grant. F3 · derivative.expiration_date: The restricted stock units vest and settle in full one year from the date of grant. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:16 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001144204-17-015094 · v461954_4.xml · derivative · entry 1 Canepa John J · CIK 0001589238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock, par value $0.01 per share · 25,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: The option shares vest in full one year from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.